RxDoctor Payments Data

Patrick Kent, MD

Infectious Disease · Greenville, SCNPI 1194250183

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations.

$2,437in general payments, 2019–2025

Across 104 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$455
  • Merck$320
  • Insmed, Inc.$312
  • Melinta Therapeutics, LLC$216
  • Viiv Healthcare Company$213
  • Paratek Pharmaceuticals, Inc.$147
  • plus $774 from 12 others

What the payments were for

  • Food & beverage$2,29894%
  • Education$1396%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,437 in reported general payments places this provider in the 70th percentile of 102 infectious disease providers in South Carolina.

See all infectious disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$54,130
Medicare patients
251
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala62$239,157
TriumeqAbacavir/Dolutegravir/Lamivudi16$56,357
OdefseyEmtricitab/Rilpiviri/Tenof Ala15$52,939
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$47,989
TivicayDolutegravir Sodium18$38,303
PifeltroDoravirine11$18,206
Voriconazole13$1,828
Cefadroxil44$1,277
Doxycycline Hyclate50$1,156
Rifampin15$1,081
Ethambutol Hcl13$668
Amoxicillin48$578
Cefazolin Sodium14$534
CeftriaxoneCeftriaxone Sodium13$489
Azithromycin19$353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$455$287,14575 claims
Viiv Healthcare CompanyTriumeq, Tivicay$213$94,66034 claims
MerckPifeltro$320$18,20611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 102 infectious disease providers in South Carolina.

Other infectious disease in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →